We are using cookies to implement functions like login, shopping cart or language selection for this website. Furthermore we use Google Analytics to create anonymized statistical reports of the usage which creates Cookies too. You will find more information in our privacy policy.
OK, I agree I do not want Google Analytics-Cookies
Journal of Oral & Facial Pain and Headache
Login:
username:

password:

Plattform:

Forgotten password?

Registration

J Orofac Pain 32 (2018), No. 2     27. Apr. 2018
J Orofac Pain 32 (2018), No. 2  (27.04.2018)

Page 130-136


Salivary Levels of Interleukin-1
Cê, Patrícia S. / Barreiro, Bernardo B. O. / Silva, Rodrigo B. M. / Oliveira, Rogério B. / Heitz, Claiton / Campos, Maria M.
Aims: To evaluate salivary levels of the proinflammatory cytokine interleukin- 1β (IL-1β) in patients with temporomandibular disorders (TMD), fibromyalgia, or both conditions in comparison to healthy individuals.
Methods: A total of 69 females (18 to 84 years of age) were assigned to one of four groups: (A) healthy controls (n = 27); (B) TMD only (n = 18); (C) fibromyalgia only (n = 15); and (D) fibromyalgia plus TMD (n = 9). Clinical data and salivary IL-1β levels were evaluated. Statistical analysis was performed by using Fischer exact test, unpaired Student t test, or one-way analysis of variance plus multiple comparisons Tukey test, depending on the variable. The correlation between age and IL-1β levels was assessed by using Pearson correlation coefficient.
Results: Most patients in groups B and D displayed clinical features of Group I (muscle disorders) and Group II (disc displacements) of the Axis I Research Diagnostic Criteria for Temporomandibular Disorders. The subjects in groups C and D presented values of > 7 on the Widespread Pain Index (WPI) and > 5 for Symptom Severity Score (SS) according to the Fibromyalgia Survey Diagnostic Criteria and Severity Scale. There were no significant differences when SS and WPI levels were compared between groups C and D. The patients with TMD showed significantly higher salivary IL-1β levels irrespective of a fibromyalgia diagnosis (groups B and D), whereas the fibromyalgia-only patients (group C) did not show any significant difference in relation to controls.
Conclusion: This study provides novel evidence indicating that salivary IL-1β may be a biomarker for TMD.